Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
PFE's Cash to Debt is ranked higher than
81% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. PFE: N/A )
Ranked among companies with meaningful Cash to Debt only.
PFE' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.90 Max: 3.47
Current: N/A
0.22
3.47
Equity to Asset 0.39
PFE's Equity to Asset is ranked lower than
80% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PFE: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
PFE' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.47 Max: 0.66
Current: 0.39
0.39
0.66
Interest Coverage 19.97
PFE's Interest Coverage is ranked lower than
67% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. PFE: 19.97 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 13.79 Max: 24.84
Current: 19.97
5.27
24.84
F-Score: 6
Z-Score: 2.20
M-Score: -2.71
WACC vs ROIC
7.97%
16.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.06
PFE's Operating margin (%) is ranked higher than
88% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. PFE: 25.06 )
Ranked among companies with meaningful Operating margin (%) only.
PFE' s Operating margin (%) Range Over the Past 10 Years
Min: 14.53  Med: 21.24 Max: 30.47
Current: 25.06
14.53
30.47
Net-margin (%) 15.85
PFE's Net-margin (%) is ranked higher than
81% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. PFE: 15.85 )
Ranked among companies with meaningful Net-margin (%) only.
PFE' s Net-margin (%) Range Over the Past 10 Years
Min: 12.67  Med: 17.17 Max: 42.65
Current: 15.85
12.67
42.65
ROE (%) 13.26
PFE's ROE (%) is ranked higher than
69% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. PFE: 13.26 )
Ranked among companies with meaningful ROE (%) only.
PFE' s ROE (%) Range Over the Past 10 Years
Min: 9.29  Med: 12.22 Max: 28.2
Current: 13.26
9.29
28.2
ROA (%) 5.58
PFE's ROA (%) is ranked higher than
60% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. PFE: 5.58 )
Ranked among companies with meaningful ROA (%) only.
PFE' s ROA (%) Range Over the Past 10 Years
Min: 4.05  Med: 6.90 Max: 16.63
Current: 5.58
4.05
16.63
ROC (Joel Greenblatt) (%) 65.69
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. PFE: 65.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.74  Med: 53.79 Max: 75.24
Current: 65.69
40.74
75.24
Revenue Growth (3Y)(%) -0.20
PFE's Revenue Growth (3Y)(%) is ranked lower than
69% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. PFE: -0.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PFE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.5  Med: 4.40 Max: 19.1
Current: -0.2
-2.5
19.1
EBITDA Growth (3Y)(%) -0.60
PFE's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. PFE: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PFE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.7  Med: 6.00 Max: 35.5
Current: -0.6
-4.7
35.5
EPS Growth (3Y)(%) 12.50
PFE's EPS Growth (3Y)(%) is ranked higher than
59% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. PFE: 12.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PFE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.8  Med: 3.60 Max: 90.5
Current: 12.5
-26.8
90.5
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PFE Guru Trades in Q1 2015

Signature Select Canadian Fund 219,000 sh (New)
Jim Simons 2,622,441 sh (New)
Paul Tudor Jones 1,138,585 sh (+195.35%)
David Dreman 25,202 sh (+70.38%)
Joel Greenblatt 1,972,788 sh (+38.84%)
John Buckingham 71,247 sh (+5.30%)
Pioneer Investments 5,671,904 sh (+4.76%)
Ken Fisher 31,208,271 sh (+0.04%)
T Rowe Price Equity Income Fund 12,737,115 sh (unchged)
Vanguard Health Care Fund 19,395,622 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
Prem Watsa 235,000 sh (unchged)
NWQ Managers 163,400 sh (unchged)
Steven Cohen 5,000,000 sh (unchged)
Ruane Cunniff 10,967 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ray Dalio Sold Out
Bestinfond Sold Out
First Eagle Investment 5,266,820 sh (-0.12%)
Richard Pzena 2,159,618 sh (-0.50%)
Manning & Napier Advisors, Inc 876,319 sh (-0.82%)
Dodge & Cox 46,776,959 sh (-0.89%)
John Keeley 98,689 sh (-1.27%)
Diamond Hill Capital 10,432,351 sh (-1.70%)
Charles Brandes 6,123,536 sh (-2.37%)
Jeremy Grantham 33,095 sh (-2.46%)
Kahn Brothers 1,811,016 sh (-3.83%)
RS Investment Management 2,600,485 sh (-4.37%)
Murray Stahl 60,746 sh (-5.17%)
Mario Gabelli 896,431 sh (-5.80%)
NWQ Managers 5,927,532 sh (-6.64%)
Mairs and Power 2,363,506 sh (-11.07%)
James Barrow 55,080,222 sh (-12.24%)
Jeff Auxier 98,929 sh (-31.62%)
Steven Cohen 450,000 sh (-62.85%)
Louis Moore Bacon 125,000 sh (-77.27%)
» More
Q2 2015

PFE Guru Trades in Q2 2015

Ray Dalio 79,108 sh (New)
Kyle Bass 63,675 sh (New)
Jeremy Grantham 5,991,393 sh (+18003.62%)
John Keeley 129,055 sh (+30.77%)
Murray Stahl 62,776 sh (+3.34%)
John Buckingham 73,071 sh (+2.56%)
Ken Fisher 31,816,749 sh (+1.95%)
James Barrow 55,354,855 sh (+0.50%)
Richard Pzena 2,159,818 sh (+0.01%)
Robert Bruce 455,332 sh (unchged)
Louis Moore Bacon 800,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
Vanguard Health Care Fund 19,395,622 sh (unchged)
Steven Cohen 2,500,000 sh (unchged)
T Rowe Price Equity Income Fund 12,737,115 sh (unchged)
Ruane Cunniff 10,967 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Mairs and Power 2,351,483 sh (-0.51%)
David Dreman 24,926 sh (-1.10%)
Charles Brandes 6,054,883 sh (-1.12%)
Diamond Hill Capital 10,234,918 sh (-1.89%)
Kahn Brothers 1,774,875 sh (-2.00%)
Dodge & Cox 45,234,031 sh (-3.30%)
Mario Gabelli 819,901 sh (-8.54%)
Manning & Napier Advisors, Inc 793,722 sh (-9.43%)
Jeff Auxier 86,322 sh (-12.74%)
Pioneer Investments 4,669,110 sh (-17.68%)
First Eagle Investment 4,315,476 sh (-18.06%)
Jim Simons 2,081,041 sh (-20.64%)
RS Investment Management 1,955,985 sh (-24.78%)
NWQ Managers 4,372,936 sh (-26.23%)
Joel Greenblatt 1,024,564 sh (-48.07%)
Paul Tudor Jones 15,600 sh (-98.63%)
» More
Q3 2015

PFE Guru Trades in Q3 2015

Lee Ainslie 6,937,928 sh (New)
Leon Cooperman 4,830,595 sh (New)
Louis Moore Bacon 350,000 sh (New)
John Burbank 1,292,832 sh (New)
Ray Dalio 345,708 sh (+337.01%)
Paul Tudor Jones 28,300 sh (+81.41%)
First Eagle Investment 6,090,294 sh (+41.13%)
Mairs and Power 3,063,915 sh (+30.30%)
Pioneer Investments 5,617,211 sh (+20.31%)
Jeremy Grantham 6,293,591 sh (+5.04%)
Murray Stahl 65,741 sh (+4.72%)
Ruane Cunniff 11,302 sh (+3.05%)
Joel Greenblatt 1,047,861 sh (+2.27%)
Diamond Hill Capital 10,380,922 sh (+1.43%)
Ken Fisher 31,926,879 sh (+0.35%)
Dodge & Cox 45,266,436 sh (+0.07%)
Jeff Auxier 86,322 sh (unchged)
Steven Cohen 2,200,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
NWQ Managers 217,300 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Richard Pzena 2,159,818 sh (unchged)
Signature Select Canadian Fund Sold Out
Kyle Bass Sold Out
Jim Simons Sold Out
NWQ Managers 4,357,477 sh (-0.35%)
John Buckingham 72,589 sh (-0.66%)
T Rowe Price Equity Income Fund 12,599,315 sh (-1.08%)
John Keeley 126,755 sh (-1.78%)
James Barrow 54,274,453 sh (-1.95%)
Charles Brandes 5,863,701 sh (-3.16%)
Manning & Napier Advisors, Inc 757,703 sh (-4.54%)
Kahn Brothers 1,671,039 sh (-5.85%)
RS Investment Management 1,819,885 sh (-6.96%)
Mario Gabelli 730,005 sh (-10.96%)
Vanguard Health Care Fund 12,550,992 sh (-35.29%)
David Dreman 6,443 sh (-74.15%)
» More
Q4 2015

PFE Guru Trades in Q4 2015

T Rowe Price Equity Income Fund 14,525,000 sh (+15.28%)
John Buckingham 76,884 sh (+5.92%)
Ken Fisher 32,334,417 sh (+1.28%)
Richard Pzena 2,161,593 sh (+0.08%)
Jeff Auxier 86,224 sh (-0.11%)
James Barrow 53,862,996 sh (-0.76%)
Mario Gabelli 706,956 sh (-3.16%)
Kahn Brothers 1,569,873 sh (-6.05%)
Vanguard Health Care Fund 8,872,226 sh (-29.31%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.86
PFE's P/E(ttm) is ranked higher than
66% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.00 vs. PFE: 21.86 )
Ranked among companies with meaningful P/E(ttm) only.
PFE' s P/E(ttm) Range Over the Past 10 Years
Min: 7.67  Med: 16.09 Max: 25.81
Current: 21.86
7.67
25.81
Forward P/E 11.34
PFE's Forward P/E is ranked higher than
78% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.75 vs. PFE: 11.34 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.77
PFE's PE(NRI) is ranked higher than
65% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.90 vs. PFE: 21.77 )
Ranked among companies with meaningful PE(NRI) only.
PFE' s PE(NRI) Range Over the Past 10 Years
Min: 9.77  Med: 19.06 Max: 25.68
Current: 21.77
9.77
25.68
P/B 2.65
PFE's P/B is ranked higher than
50% of the 935 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. PFE: 2.65 )
Ranked among companies with meaningful P/B only.
PFE' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.40 Max: 3.32
Current: 2.65
1.32
3.32
P/S 3.82
PFE's P/S is ranked lower than
70% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. PFE: 3.82 )
Ranked among companies with meaningful P/S only.
PFE' s P/S Range Over the Past 10 Years
Min: 2.31  Med: 4.76 Max: 6.49
Current: 3.82
2.31
6.49
PFCF 13.16
PFE's PFCF is ranked higher than
85% of the 468 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.49 vs. PFE: 13.16 )
Ranked among companies with meaningful PFCF only.
PFE' s PFCF Range Over the Past 10 Years
Min: 5.02  Med: 12.82 Max: 18.67
Current: 13.16
5.02
18.67
POCF 12.03
PFE's POCF is ranked higher than
78% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.33 vs. PFE: 12.03 )
Ranked among companies with meaningful POCF only.
PFE' s POCF Range Over the Past 10 Years
Min: 4.56  Med: 11.39 Max: 15.89
Current: 12.03
4.56
15.89
EV-to-EBIT 20.66
PFE's EV-to-EBIT is ranked lower than
53% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.09 vs. PFE: 20.66 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.3  Med: 17.80 Max: 31.6
Current: 20.66
8.3
31.6
EV-to-EBITDA 14.88
PFE's EV-to-EBITDA is ranked higher than
56% of the 839 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.61 vs. PFE: 14.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 12.10 Max: 17.6
Current: 14.88
5.8
17.6
PEG 5.17
PFE's PEG is ranked lower than
73% of the 278 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. PFE: 5.17 )
Ranked among companies with meaningful PEG only.
PFE' s PEG Range Over the Past 10 Years
Min: 0.93  Med: 2.66 Max: 31.98
Current: 5.17
0.93
31.98
Shiller P/E 16.19
PFE's Shiller P/E is ranked higher than
86% of the 169 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.01 vs. PFE: 16.19 )
Ranked among companies with meaningful Shiller P/E only.
PFE' s Shiller P/E Range Over the Past 10 Years
Min: 9.05  Med: 16.29 Max: 25.62
Current: 16.19
9.05
25.62
Current Ratio 1.62
PFE's Current Ratio is ranked lower than
65% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. PFE: 1.62 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.65 Max: 3.18
Current: 1.62
1.1
3.18
Quick Ratio 1.34
PFE's Quick Ratio is ranked lower than
59% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. PFE: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.43 Max: 2.86
Current: 1.34
0.84
2.86
Days Inventory 197.24
PFE's Days Inventory is ranked lower than
79% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. PFE: 197.24 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 234.41 Max: 344.63
Current: 197.24
185.33
344.63
Days Sales Outstanding 71.24
PFE's Days Sales Outstanding is ranked higher than
53% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. PFE: 71.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.79  Med: 71.08 Max: 106.89
Current: 71.24
63.79
106.89
Days Payable 124.63
PFE's Days Payable is ranked higher than
75% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. PFE: 124.63 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 106.01 Max: 179.46
Current: 124.63
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.92
PFE's Dividend Yield is ranked higher than
86% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. PFE: 3.92 )
Ranked among companies with meaningful Dividend Yield only.
PFE' s Dividend Yield Range Over the Past 10 Years
Min: 2.27  Med: 3.63 Max: 10.4
Current: 3.92
2.27
10.4
Dividend Payout 0.83
PFE's Dividend Payout is ranked higher than
97% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. PFE: 0.83 )
Ranked among companies with meaningful Dividend Payout only.
PFE' s Dividend Payout Range Over the Past 10 Years
Min: 0.12  Med: 0.50 Max: 8.21
Current: 0.83
0.12
8.21
Dividend Growth (3y) 9.10
PFE's Dividend Growth (3y) is ranked higher than
56% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. PFE: 9.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PFE' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -14.7  Med: 14.45 Max: 22.6
Current: 9.1
-14.7
22.6
Forward Dividend Yield 4.20
PFE's Forward Dividend Yield is ranked higher than
87% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 4.20 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.42
PFE's Yield on cost (5-Year) is ranked higher than
87% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. PFE: 5.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PFE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.14  Med: 5.02 Max: 14.38
Current: 5.42
3.14
14.38
3-Year Average Share Buyback Ratio 6.50
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. PFE: 6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -1.05 Max: 6.5
Current: 6.5
-17.9
6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.94
PFE's Price/Projected FCF is ranked higher than
91% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.22 vs. PFE: 0.94 )
Ranked among companies with meaningful Price/Projected FCF only.
PFE' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.11 Max: 8.57
Current: 0.94
0.53
8.57
Price/Median PS Value 1.10
PFE's Price/Median PS Value is ranked higher than
66% of the 924 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. PFE: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
PFE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.51  Med: 1.18 Max: 3.71
Current: 1.1
0.51
3.71
Earnings Yield (Greenblatt) (%) 4.92
PFE's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. PFE: 4.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 5.60 Max: 12.1
Current: 4.92
3.2
12.1
Forward Rate of Return (Yacktman) (%) 10.68
PFE's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. PFE: 10.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PFE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9  Med: 15.50 Max: 23.2
Current: 10.68
9
23.2

More Statistics

Revenue(Mil) $48851
EPS $ 1.24
Beta1.02
Short Percentage of Float2.01%
52-Week Range $28.25 - 36.46
Shares Outstanding(Mil)6173.00

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 48,574 57,745 62,885 66,480
EPS($) 2.17 2.35 2.52 2.85
EPS without NRI($) 2.17 2.35 2.52 2.85

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.
» More Articles for NYSE:PFE

Headlines

Articles On GuruFocus.com
Kahn Brothers Sells Part of Stake in Pfizer in 4th Quarter Feb 09 2016 
Is Apple the Next Altria? Feb 02 2016 
UnitedHealth Likely to Build on Growth in the Health Care Sector Jan 05 2016 
Third Avenue Management's Annual Report Dec 29 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
A Fed Rate Hike: What Investment Options Await You Dec 15 2015 
Cooperman's Big Bets Include Alphabet, Pfizer Dec 06 2015 
Leon Cooperman Adds Google Holdings and Buys Pfizer Nov 23 2015 
What's Lee Ainslie's Angle to Buy Into a Pharmaceutical Stalwart Yielding 3%? Nov 19 2015 

More From Other Websites
Panel Recommends FDA Approval of Remicade Knockoff Feb 09 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 09 2016
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The... Feb 09 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
Pfizer, Reynolds Among Recession Stock Plays — GE, GM For Recovery Feb 09 2016
What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) Feb 09 2016
Pfizer’s Loss of Product Exclusivity Affected Its 4Q15 Revenues Feb 09 2016
Pfizer Reported 7% Top Line Growth in 4Q15 Feb 09 2016
Pfizer (PFE) Stock Rises, BofA/Merrill Lynch Names Top Pick Feb 09 2016
Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All... Feb 09 2016
[$$] Pfizer seeks to soothe fears over R&D Feb 09 2016
Senator scrutinizes pharma links on government pain panel Feb 08 2016
Senator scrutinizes pharma links on government pain panel Feb 08 2016
Pfizer To Reorganize After Allergan Buyout, With Saunders President Feb 08 2016
The market in a minute: 5 stocks I really like Feb 08 2016
Pfizer unveils management line up for combined company Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK